These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 21552005)

  • 1. Response to commentaries.
    Light DW
    Hum Vaccin; 2011 May; 7(5):496. PubMed ID: 21552005
    [No Abstract]   [Full Text] [Related]  

  • 2. Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda.
    Tate JE; Kisakye A; Mugyenyi P; Kizza D; Odiit A; Braka F
    Vaccine; 2011 Apr; 29(17):3329-34. PubMed ID: 21241733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why it is still important that countries know the burden of pneumococcal disease.
    Prato R; Tafuri S; Fortunato F; Martinelli D
    Hum Vaccin; 2010 Nov; 6(11):918-21. PubMed ID: 21045538
    [No Abstract]   [Full Text] [Related]  

  • 4. Summaries for patients. Cost-effectiveness of pneumococcal vaccine for people 50 through 64 years of age.
    Ann Intern Med; 2003 Jun; 138(12):I42. PubMed ID: 12809479
    [No Abstract]   [Full Text] [Related]  

  • 5. Challenges in cost-effectiveness analyses of hospital interventions to improve quality.
    Davis MM
    Infect Control Hosp Epidemiol; 2008 May; 29(5):395-7. PubMed ID: 18419359
    [No Abstract]   [Full Text] [Related]  

  • 6. A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children.
    Vemer P; Postma MJ
    Hum Vaccin Immunother; 2014; 10(7):1841-9. PubMed ID: 25424791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What do the next 100 years hold for pneumococcal vaccination?
    Rijkers GT; van Mens SP; van Velzen-Blad H
    Expert Rev Vaccines; 2010 Nov; 9(11):1241-4. PubMed ID: 21087102
    [No Abstract]   [Full Text] [Related]  

  • 8. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress in vaccines, progress in health economics.
    Annemans L
    Vaccine; 2010 Nov; 28 Suppl 6():G1-2. PubMed ID: 21075264
    [No Abstract]   [Full Text] [Related]  

  • 10. Protecting children with HIV against pneumococcal disease.
    Meehan A; Mackenzie G; Shingadia D; Booy R
    Lancet Infect Dis; 2009 Jul; 9(7):394-5. PubMed ID: 19555896
    [No Abstract]   [Full Text] [Related]  

  • 11. No Benefit to Delaying Pneumococcal Polysaccharide Vaccination in HIV-Positive Adults.
    Leggat DJ; Iyer AS; Westerink MA
    J Infect Dis; 2015 Dec; 212(11):1851-2. PubMed ID: 26109676
    [No Abstract]   [Full Text] [Related]  

  • 12. Universal pneumococcal vaccination for India.
    Mathew JL
    Indian Pediatr; 2008 Feb; 45(2):160-1. PubMed ID: 18310801
    [No Abstract]   [Full Text] [Related]  

  • 13. Pneumococcal vaccination for Indian children.
    Levine OS; Cherian T
    Indian Pediatr; 2007 Jul; 44(7):491-6. PubMed ID: 17684301
    [No Abstract]   [Full Text] [Related]  

  • 14. The heptavalent conjugate pneumococcal vaccine and its implications for managed care--clinical overview and roundtable discussions.
    Alexander PG; Chartrand SA; Davies TJ; Gaines BM; Oster G; Shurin P; Tamsky L; Thornton DK; Wittert W
    Manag Care Interface; 2001; Suppl C():10-28; quiz 29-30. PubMed ID: 11724029
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.
    Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J
    Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.
    Postma MJ; Heijnen ML; Beutels P; Jager JC
    Expert Rev Vaccines; 2003 Aug; 2(4):477-82. PubMed ID: 14711333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adherence to pneumococcal conjugate vaccination schedule and uptake rate as compared to the established diphtheria-tetanus-acellular pertussis vaccination in Cyprus.
    Hadjipanayis A; Efstathiou E; Michaelidou K; Papaevangelou V
    Vaccine; 2018 Sep; 36(38):5685-5691. PubMed ID: 30115523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumococcal vaccination in developing countries: where does science end and commerce begin?
    Mathew JL
    Vaccine; 2009 Jul; 27(32):4247-51. PubMed ID: 19389448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).
    Díez-Domingo J; Ridao-López M; Gutiérrez-Gimeno MV; Puig-Barberá J; Lluch-Rodrigo JA; Pastor-Villalba E
    Vaccine; 2011 Dec; 29(52):9640-8. PubMed ID: 22027484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic evaluation of standing order programs for pneumococcal vaccination of hospitalized elderly patients.
    Middleton DB; Lin CJ; Smith KJ; Zimmerman RK; Nowalk MP; Roberts MS; Fox DE
    Infect Control Hosp Epidemiol; 2008 May; 29(5):385-94. PubMed ID: 18521990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.